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Oral Presentations S165expansion of remaining families of Firmicutes (Table). UponHSCT,
these mice developed fulminant GVHD compared to their counter-
parts who did not receive ampicillin (p\ .01). Interestingly, oral ga-
vage with Lactobacillaceae following ampicillin appears to prevent
exacerbation of GVHD.
Altogether, our results suggest that during GVHD, an increase of
Lactobacillaceae in the gut may be a compensatory mechanism to re-
duce GVHD severity. Moreover, antibiotics prior to HSCT could
predispose to GVHD, while the administration of Lactobacillaceae
can be explored as GVHD prophylaxis.
Table 1. Bacterial family representation in ileal contents
% other
% Lactobacillaceae FirmicutesNormal B6 mice 42±3 26±1
HSCT mice without GVHD 54±2 27±2
HSCT mice with GVHD 95±2 2±0.5
B6 mice after ampicillin and recovery 0±0.1 98±136
SINGLE NUCLEOTIDE POLYMORPHISM (SNP)-BASED PREDICTIVE
MODELS FOR GRAFT-VERSUS-HOST DISEASE (GVHD) IDENTIFY HIGH
RISK PATIENTS FOR OVERALL AND ORGAN SPECIFIC GVHD FOLLOWING
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Introduction: The present study attempted to identify potential
predictive SNP marker associating with the risk of acute (aGVHD)
or chronic GVHD (cGVHD) and organ specific GVHDs. In addi-
tion, SNP markers predicting transplant outcomes such as overall
survival (OS), relapse free survival (RFS) or non relapse mortality
(NRM) were also analyzed with 259 SNPs in 54 genes which are po-
tentially involved in the pathogenesis of GVHD.
Materials andMethods: 394 pairs of donors and recipients were in-
cluded and their germline DNA samples were genotype for 259
SNPs in 54 genes using MALDI-TOF based platform. The Risk
of aGVHD/cGVHD and organ specific GVHD were evaluated as
well as RFS, NRM and OS in patients receiving related donor trans-
plantation (n 5 303). After multivariate analyses, the predictive
model generated by combination of clinical and genetic SNP
markers were attmpted to stratify patients into low (\Q1), moderate
(Q2,3) and high risk groups (Q4), which were to be validated in 84
pairs receiving MUD transplantation. Finally, we performed C-sta-
tistic analysis for each transplant outcome in a pooled population (n
5 394).
Results: Several SNP markers in the cytokine, apoptosis, TGF-b or
PDGF mediated pathways were identified as potential predictive of
aGVHD/cGVHD. Of interest,NOS2 (nitric oxide 2) was associated
with the risk of cutaneous or aGVHD. PDGF-mediated pathway
was involved in the pathogenesis of cutaneous GVHD. These pre-
dictive models generated with both clinical and genetic factors
were statistically significant (P\ 0.001) except for overall cGVHD
(p 5 0.07). The genetic predictive models have been replicated in
validation cohort in terms of skin cGVHD (p \ 0.0001), skin
aGVHD (p 5 0.0219), aGVHD (p 5 0.0274), and RFS (p 5
0.0166). The C-statistics have been increased by median of 0.0745
(range 0.023-0.18, mean 0.0788) when adopted the predictive model
generated combined with clinical and genetic factors compared to
that generated only by clinical factors.
Conclusions: The present study suggested that 1) the predictive
models improved stratification of the patients according to their
transplant outcomes and the risk of GVHD (esp. organ specific
GVHD) using donor-/recipient-SNP markers, and 2) the predictive
models incorporating clinical and genetic factors were suggested to
enhance stratification power predicting the prognosis of transplant
patients and the risk of GVHD.37
UNIVERSAL ROLE FOR HLA-C AND KIR2DL LIGAND MISMATCH IN
SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE AFTER UNRELATED
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JAPANESE AND CAUCASIAN TRANSPLANT RECIPIENTS: AN ANALYSIS
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Donor HLA mismatching is a known risk factor for morbidity and
mortality after unrelated hematopoietic cell transplantation (HCT).
The frequency of donor and recipient HLA phenotypes differs be-
tween ethnically diverse populations, as does the incidence of acute
graft-versus-host disease (GVHD). Certain high-risk HLA mis-
matches are responsible for acute GVHD risk in the Japanese experi-
ence (Kawase et al Blood 2007). We tested the hypothesis that
clinical outcome after HLA-C mismatched unrelated HCT depends
on the specific mismatch combinations, and that risks are different de-
pending on theHLAphenotypes of the transplant population.The In-
ternational Histocompatibility Working Group dataset enables us to
compare clinical outcome between Caucasian and Japanese popula-
tions to test these hypotheses. High resolution HLA typing was avail-
able for the Japanese (n 5 5986) and Caucasian pairs (n 5 9379).
Multivariable Cox regression models adjusted for HLAmatching sta-
tus other than HLA-C and non-HLA factors known to influence
GVHD risk. In both Japanese and Caucasian recipients, the presence
of an HLA-C mismatch/KIR ligand match was associated with in-
creased risk of grades III-IV acute GVHD compared to an HLA-C
match (HR 1.69 [p \ 0.001] and 1.23 [p \ 0.001], respectively).
KIR2DL ligand mismatching had an even stronger effect among the
Japanese than the Caucasian recipients (HRs for HLA-C allele mis-
match and KIR mismatch in GVH direction were 2.51 (p\ 0.001)
and 1.21 (p5 0.017), respectively). Since it is known that certain mis-
matches that occur in the Japanese population occur very infrequently
(if at all) in theCaucasian population, and vice verse, we conducted the
sameanalysesbut limited to subjectswhohaveHLA-Cmismatchcom-
binations occurring in more than 10 subjects in both populations.
Compared to HLA-Cmatches, HLA-C mismatch/KIR ligand match
and HLA-C mismatch/KIR ligand mismatch were associated with
a statistically significantly increased risk of GVHD in Japanese (HR
1.39 [p5 0.003] andHR3.13 [p\0.001], respectively) but not inCau-
casian recipients (HR 1.18 [p 5 0.128] and HR 0.91 [p 5 0.588]).
These results suggest that the magnitude of risks associated with
HLA-C disparity after unrelated HCT may be different in recipients
of Japanese compared to Caucasian background, particularly in the
presence of a KIR ligandmismatch. Risks may also depend on the spe-
cific HLA-C allele mismatch combinations.
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A PROSPECTIVE PHASE I/II TRIAL OF BORTEZOMIB-BASED GRAFT-
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STEM CELL TRANSPLANTATION: ENCOURAGING SAFETY, EFFICACY,
AND SURVIVAL
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Introduction: The challenge in RIC HSCT is to prevent GVHD
but maintain GVL and immunologic reconstitution. Bortezomib is
an excellent candidate immunomodulator. In addition to antitumor
activity via NF-kB and other pathways, it inhibits APC by attenuat-
ing TLR-4 mediated activation and cytokine production. In mouse
models, bortezomib preferentially and specifically depletes alloreac-
tive T cells, and prevents GVHD without impairing engraftment or
S166 Oral PresentationsGVL. We report a completed phase I/II study of bortezomib-based
GVHD prophylaxis in 1-2 locus HLA-mismatched (A, B, C, DRB1,
DQB1) unrelated donor (MMUD) RIC HSCT. Phase I data docu-
mentedMTDand safety of a regimen of bortezomib (1.3mg/m2; day
11, 14, 17), methotrexate and tacrolimus.
Patients: 45 patients with a median age of 59 years (range, 27-72)
were enrolled. Donor mismatch: HLA-A (12), B (10), C (14),
DRB1 (2), DQB1 (2), B1C (4), DRB11DQB1 (1); 1-antigen (28),
2-antigen (3), 1-allele (11), 2-allele (1), 1-antigen11-allele (2). Dis-
ease: AML (14), NHL (11), CLL/PLL (8), HD (4), MDS (4), ALL
(2), MPD (2). 8 had prior transplants. Median follow-up in survivors
was 12.5 months (range, 3.3-37.2).
Results: Median time to PMN and platelet engraftment was 13
(range, 6-29) and 20 days (range, 13-27) respectively; notably 23 pa-
tients had no PMN nadir and 21 had no platelet nadir. 1 patient failed
to engraft and 4 did not sustain graft chimerism $ 70% through day
1100 in the absence of disease relapse/progression. Median day 130
and 1100 chimerism was 97% and 99% respectively. 15 patients re-
lapsed. 9 patients died: relapse-6; bacterial infection-2; CNS hemor-
rhage-1. 11 had grade 2-4 acute GVHD (gr-2:8; gr-3:3). 16 had
chronic GVHD requiring systemic therapy. No neuropathy flare or
colonic necrosis was noted. Adjusted for competing risks, 6-month
cumulative incidence of grade 2-4 acute GVHD is 24% (95% CI,
13-38); and 1-year cumulative incidence of NRM is 7% (95% CI,
2-18), relapse is 32% (95% CI, 18-47), and chronic GVHD is 39%
(95% CI, 23-55). 1-year progression-free survival is 61% (95% CI,
44-74), and overall survival is 77% (95% CI, 60-87). Preliminary
data suggest improved T-cell reconstitution with this regimen.
Conclusion: Bortezomib-based therapy enabled GVHD control af-
ter MMUD HSCT without impaired immunologic reconstitution,
relapse, orNRM. 1-year survival is encouraging. Proteasome-inhibi-
tion should be evaluated in a randomized GVHD prevention trial.39
STATINS SYNERGIZE WITH CYCLOSPORINE IN INHIBITING MITOCHON-
DRIAL FUNCTION IN ACTIVATED T CELLS
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In a large retrospective analysis of outcomes among 567 recipients
of HLA-identical hematopoietic cell transplantation (HCT), we
found that prior treatment of donors with statins, a class of drugs
with cholesterol-lowering and immune-modulating effects, was asso-
ciated with profound protection against severe acute GVHD (Rotta et
al., Blood. 2010;115:1288). The protective effect was restricted to re-
cipients given cyclosporine (CSP)-based postgrafting immunosup-
pression and not observed among those given tacrolimus (TAC).
Based on the unexpected effect-association between statins and
CSP, we hypothesized that CSP and statins synergize in inducing
T cell hyporesponsiveness at the level of the mitochondrial mem-
brane by interacting with a number of cyclophilins, including cyclo-
philin D. To mimic the clinical HCT setting where donors are
treated with statins and recipients are given immunosuppressive
therapy with either CSP orTAC, wemeasured the bioenergeticmet-
abolic status (mitochondrial function) of T cells obtained from dogs
that were treated with statins in vivo as a function of activation ex vivo
in the presence of CSP or TAC. Specifically, dogs (n 5 3) were
treated with atorvastatin (2 mg/kg/day) and, after 3 weeks of statin
treatment, peripheral blood T cells were purified and activated
with concanavalin A (conA) in the presence of suboptimal concentra-
tions of either CSP (30 ng/mL) or TAC (0.1 ng/mL). Mitochondrial
function was then evaluated by serial real-time measurements of the
oxygen consumption rate (OCR) as an indicator of oxidative phos-
phorylation by using the Seahorse XF24 Extracellular Flux Analyzer.
In the presence of CSP, T cells from dogs treated in vivowith ator-
vastatin (n 5 3), total oxygen consumption during the first 5 hours
after conA-activation was reduced by 41% (p 5 0.12), 70% (p 5
0.005) and 100% (p 5 0.008), respectively, compared to T cells ac-
tivated in the absence of CSP. This statin-induced reduction inOCR
was not observed when in vivo statin-exposed T cells were activated
in the presence of TAC. Neither CSP nor TAC significantly sup-
pressed OCR in control T cells obtained from dogs that were nottreated with atorvastatin (n5 3). In summary, these findings support
our hypothesis that statins and CSP have synergistic inhibitory ef-
fects onmitochondrial function in activatedT cells, and they provide
a first step toward defining the key mechanisms of statin-mediated
protection against GVHD.40
DONOR Th17 AND Th1 CONTRIBUTE TO CHRONIC GRAFT-VERSUS-HOST
DISEASE
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Chronic graft-versus-host disease (cGVHD) remains a major cause
of late death and morbidity after allogeneic hematopoietic cell trans-
plantation, and the treatment of cGVHD remains challenging. To in-
vestigate the roles of Th17 cells and other Th subsets (Th1 and Th2)
in cGVHD, we first assessed the kinetics of Th cytokines in the
B10.D2 (H-2d)/ BALB/c (H-2d) model of cGVHD. In the early
phase (day 14) of post bone marrow transplant (BMT), donor T cells
produced significantly less IL-17 in the peripheral lymph nodes
(PLNs) of recipients in allogeneic BMT than in syngeneic BMT
(1.6860.09% vs. 4.3060.53%, p \ 0.01), while in the late phase
(day 28) donor T cells that produced IL-17 were increased signifi-
cantly in allogeneic recipients, compared with syngeneic controls
(7.7660.27% vs. 1.6160.16%, p\ 0.005). Next, we evaluated the
role of Th17 on cGVHD using IL-17-deficient mice on a B10.D2
background as donor mice. Upon transfer of IL-172/2 donor T cells,
skin cGVHDwas significantly ameliorated, as compared to recipients
of wild-type (WT) T cells (p 5 0.02). Histopathological examination
of the skin showed significantly reduced cGVHD pathology in recip-
ients of IL-172/2 donors (3.1761.09 vs. 8.5060.84, p5 0.006). Flow
cytometry analysis of the PLNs in the early phase (day 14) showed no
differences in Th1, Th2, and Tregs, while recipients of IL-172/2 had
significantly fewer Th1 (p\ 0.05) and Th17/Th1 (p\ 0.01) cells on
day 35. Furthermore, BMT from IFN-g2/2 B10.D2 donors signifi-
cantly improved the clinical cGVHD score, compared with WT do-
nors (p \ 0.05). Interestingly, in the early phase (day 14) of post
BMT, IFN-g2/2 donor T cells produced significantly more IL-17
in the PLNs than WT donor (4.4260.65% vs. 1.7160.27%, p \
0.01), while in the late phase (day 35), IFN-g2/2 donor T cells that
produced IL-17were decreased. Finally, we demonstrated that the ad-
ministration of ATRA or Am80, significantly decreased skin fibrosis
and alopecia, a dominant feature of cutaneous cGVHD. Flow cytom-
etry analysis of the PLNs on day 16 showed significant reductions in
Th1 and Th17 in Am80-treated recipients, as compared to controls.
Taken together, Th17, especially in the late-chronic phase, and Th1
contribute to the development of cGVHD by promoting the produc-
tion of proinflammatory cytokines. Targeting Th17 and Th1 may be
a promising strategy for preventing and treating cGVHD.41
SUPERIOR ENGRAFTMENT AND SURVIVAL AND LESS GVHD IN NOD-SCID
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Background: Direct intrabone (IB) transplantation has been sug-
gested as a method to improve hematopoietic engraftment. An addi-
tional benefit may be an abrogation of graft versus host disease
(GVHD). In mouse models, IB injection of allogeneic splenocytes
prevents murine GVHD attributable to the immunosuppressive ef-
fect of the bone marrow stromal environment. The NSG mouse
